See more : CDRL S.A. (CDL.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Eisai Co., Ltd. (ESALY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eisai Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Blue Ocean Acquisition Corp (BOCNW) Income Statement Analysis – Financial Results
- Cathay Pacific Airways Limited (CPCAY) Income Statement Analysis – Financial Results
- Sumco Corporation (SUOPY) Income Statement Analysis – Financial Results
- The Connecticut Light and Power Company (CNLTL) Income Statement Analysis – Financial Results
- Markforged Holding Corporation (MKFG) Income Statement Analysis – Financial Results
Eisai Co., Ltd. (ESALY)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.eisai.co.jp
About Eisai Co., Ltd.
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 756.23B | 645.94B | 695.62B | 642.83B | 600.05B | 539.10B | 547.92B | 548.47B | 600.35B | 573.68B | 647.93B | 768.93B | 803.14B | 781.71B | 734.42B | 674.18B | 601.26B | 533.14B | 500.13B | 466.61B | 431.75B | 361.71B | 302.47B |
| Cost of Revenue | 174.83B | 161.31B | 175.69B | 184.49B | 201.25B | 195.91B | 194.46B | 193.60B | 188.16B | 174.11B | 173.35B | 167.78B | 160.73B | 152.41B | 118.94B | 109.37B | 104.51B | 98.61B | 97.18B | 102.47B | 101.57B | 98.60B | 91.68B |
| Gross Profit | 581.40B | 484.63B | 519.93B | 458.34B | 398.80B | 343.19B | 353.46B | 354.87B | 412.20B | 399.57B | 474.57B | 601.15B | 642.41B | 629.29B | 615.48B | 564.81B | 496.75B | 434.53B | 402.95B | 364.15B | 330.18B | 263.11B | 210.79B |
| Gross Profit Ratio | 76.88% | 75.03% | 74.74% | 71.30% | 66.46% | 63.66% | 64.51% | 64.70% | 68.66% | 69.65% | 73.24% | 78.18% | 79.99% | 80.50% | 83.81% | 83.78% | 82.62% | 81.50% | 80.57% | 78.04% | 76.47% | 72.74% | 69.69% |
| Research & Development | 171.74B | 150.30B | 140.12B | 144.84B | 139.58B | 112.48B | 122.31B | 131.91B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 225.43B | 108.30B | 93.25B | 78.33B | 69.02B | 59.70B | 55.04B | 49.61B | 46.70B |
| General & Administrative | 366.43B | 281.40B | 256.30B | 228.21B | 183.86B | 179.68B | 192.82B | 194.55B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 366.43B | 281.40B | 256.30B | 228.21B | 183.86B | 179.68B | 192.82B | 194.55B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Other Expenses | -10.52B | 1.17B | -1.99B | -866.00M | -1.85B | -8.03B | -13.60B | 80.00M | 341.09B | 329.10B | 378.82B | 488.03B | 556.00B | 537.48B | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 0.00 | -130.00M | -96.00M |
| Operating Expenses | 527.65B | 432.87B | 394.43B | 372.19B | 321.59B | 284.13B | 301.53B | 326.53B | 341.09B | 329.10B | 378.82B | 488.03B | 556.00B | 537.48B | 597.73B | 459.55B | 401.04B | 347.72B | 319.88B | 288.15B | 257.49B | 204.14B | 173.66B |
| Cost & Expenses | 702.48B | 594.18B | 570.12B | 556.68B | 522.84B | 480.03B | 495.99B | 520.13B | 529.25B | 503.21B | 552.17B | 655.81B | 716.73B | 689.90B | 716.67B | 568.91B | 505.55B | 446.33B | 417.06B | 390.62B | 359.06B | 302.75B | 265.34B |
| Interest Income | 2.40B | 2.15B | 4.02B | 4.86B | 2.56B | 1.85B | 2.02B | 2.43B | 963.00M | 1.12B | 815.00M | 997.00M | 1.25B | 3.17B | 5.33B | 5.12B | 3.35B | 1.70B | 1.34B | 1.47B | 2.78B | 0.00 | 0.00 |
| Interest Expense | 1.69B | 1.36B | 1.46B | 1.56B | 2.97B | 3.24B | 3.49B | 4.89B | 5.55B | 6.69B | 6.89B | 7.42B | 7.66B | 7.63B | 762.00M | 65.00M | 79.00M | 52.00M | 28.00M | 56.00M | 296.00M | 687.00M | 1.13B |
| Depreciation & Amortization | 38.40B | 36.30B | 33.70B | 26.84B | 26.18B | 26.48B | 34.06B | 38.94B | 48.52B | 51.09B | 48.69B | 51.26B | 57.37B | 58.63B | 34.40B | 26.80B | 24.99B | 22.45B | 18.49B | 15.33B | 15.33B | 15.00B | 15.14B |
| EBITDA | 96.79B | 89.85B | 162.53B | 114.76B | 103.37B | 84.51B | 87.91B | 69.51B | 112.05B | 128.94B | 149.81B | 160.86B | 138.78B | 136.08B | 55.34B | 136.68B | 120.71B | 109.80B | 101.59B | 27.81B | 78.52B | 58.65B | 13.34B |
| EBITDA Ratio | 12.80% | 13.91% | 23.36% | 17.85% | 17.23% | 15.68% | 16.04% | 12.67% | 18.66% | 22.48% | 23.12% | 20.92% | 17.28% | 17.41% | 7.53% | 20.27% | 20.08% | 20.60% | 20.31% | 5.96% | 18.19% | 16.21% | 4.41% |
| Operating Income | 58.39B | 51.77B | 125.50B | 86.15B | 77.21B | 59.06B | 51.94B | 28.34B | 71.11B | 70.46B | 95.75B | 113.12B | 86.41B | 91.81B | 17.75B | 105.26B | 95.70B | 86.81B | 83.06B | 75.86B | 72.69B | 58.97B | 37.13B |
| Operating Income Ratio | 7.72% | 8.01% | 18.04% | 13.40% | 12.87% | 10.96% | 9.48% | 5.17% | 11.84% | 12.28% | 14.78% | 14.71% | 10.76% | 11.74% | 2.42% | 15.61% | 15.92% | 16.28% | 16.61% | 16.26% | 16.84% | 16.30% | 12.28% |
| Total Other Income/Expenses | -3.93B | 785.00M | 2.56B | 3.30B | -409.00M | -1.40B | -1.46B | -2.46B | -12.89B | 966.00M | -1.10B | -10.55B | -12.13B | -21.32B | -96.00M | 5.07B | 378.00M | 845.00M | -539.00M | -6.04B | -9.93B | -16.13B | -11.60B |
| Income Before Tax | 54.46B | 52.55B | 128.06B | 89.45B | 76.80B | 57.67B | 50.47B | 25.88B | 58.21B | 71.43B | 94.65B | 102.57B | 74.28B | 70.48B | 17.65B | 110.33B | 96.08B | 87.65B | 82.52B | 69.83B | 62.75B | 42.84B | 25.54B |
| Income Before Tax Ratio | 7.20% | 8.14% | 18.41% | 13.92% | 12.80% | 10.70% | 9.21% | 4.72% | 9.70% | 12.45% | 14.61% | 13.34% | 9.25% | 9.02% | 2.40% | 16.37% | 15.98% | 16.44% | 16.50% | 14.96% | 14.53% | 11.84% | 8.44% |
| Income Tax Expense | 8.74B | 10.07B | 5.60B | 22.97B | 22.38B | 15.42B | -4.57B | -17.58B | 25.03B | 22.88B | 35.71B | 34.79B | 33.41B | 22.13B | 37.19B | 39.20B | 32.23B | 31.80B | 32.93B | -28.61B | 26.10B | 19.63B | -14.20B |
| Net Income | 45.72B | 42.12B | 121.77B | 63.39B | 51.85B | 39.36B | 54.93B | 43.25B | 32.96B | 48.28B | 58.51B | 67.39B | 40.34B | 47.68B | -17.01B | 70.61B | 63.41B | 55.51B | 50.15B | 41.03B | 36.80B | 23.32B | 11.28B |
| Net Income Ratio | 6.05% | 6.52% | 17.50% | 9.86% | 8.64% | 7.30% | 10.03% | 7.89% | 5.49% | 8.42% | 9.03% | 8.76% | 5.02% | 6.10% | -2.32% | 10.47% | 10.55% | 10.41% | 10.03% | 8.79% | 8.52% | 6.45% | 3.73% |
| EPS | 159.44 | 146.94 | 424.77 | 221.12 | 180.97 | 137.63 | 192.50 | 151.67 | 115.56 | 169.38 | 205.33 | 236.52 | 141.58 | 167.35 | -59.80 | 238.10 | 221.81 | 194.22 | 174.26 | 138.34 | 126.14 | 78.67 | 38.03 |
| EPS Diluted | 159.44 | 146.94 | 424.77 | 221.12 | 180.97 | 137.42 | 192.25 | 151.53 | 115.46 | 169.31 | 205.31 | 236.51 | 141.56 | 167.30 | -59.80 | 238.10 | 221.81 | 194.22 | 174.26 | 138.34 | 126.14 | 78.67 | 38.03 |
| Weighted Avg Shares Out | 286.73M | 286.65M | 286.66M | 286.66M | 286.48M | 285.98M | 285.37M | 285.17M | 285.17M | 285.01M | 284.97M | 284.94M | 284.91M | 284.90M | 284.49M | 296.57M | 285.87M | 285.79M | 287.78M | 296.57M | 291.72M | 296.45M | 296.45M |
| Weighted Avg Shares Out (Dil) | 286.73M | 286.65M | 286.66M | 286.66M | 286.48M | 286.42M | 285.75M | 285.44M | 285.42M | 285.13M | 284.99M | 284.95M | 284.95M | 284.99M | 284.49M | 296.57M | 285.87M | 285.79M | 287.78M | 296.57M | 291.72M | 296.45M | 296.45M |
Japan's Eisai developing dementia drug for US market, Nikkei reports
Japanese drugmaker Eisai is developing a dementia treatment that it aims to commercialise in the U.S. by fiscal 2030, the Nikkei reported on Sunday.
Eisai and Biogen launch Alzheimer's drug Leqembi in China
Eisai and Biogen have launched their Alzheimer's treatment Leqembi in China, the third country after the United States and Japan, the companies said on Friday.
FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
STOCKHOLM , June 10, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for less frequent monthly lecanemab-irmb...
FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and...
FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass. , June 9, 2024 /PRNewswire/ -- Eisai Co., Ltd.
Eisai Co Ltd. (ESALF) Q4 2024 Earnings Call Transcript
Eisai Co Ltd. (OTCPK:ESALF) Q4 2024 Results Conference Call May 16, 2024 2:00 AM ET Company Participants Haruo Naito - CEO, Representative Corporate Officer & Director Keisuke Naito - SVP, Chief Strategy, Planning & Ecosystem Officer and Acting Global Alzheimer's...
EU drug regulator does not refer to Eisai-Biogen Alzheimer's drug in meeting notes
The European Union's medicines regulator did not mention Eisai and Biogen's Alzheimer's drug in its notes and recommendations on Friday.
China approves Alzheimer's treatment Leqembi by Eisai and Biogen
Eisai and Biogen said on Tuesday that their Alzheimer's treatment Leqembi had won approval in China, the third country after the United States and Japan.
Merck-Eisai uterine cancer drug combination fails first-line treatment study
Merck & Co Inc (NYSE:MRK) and Eisai announced Friday that their therapeutic combination targeting endometrial cancer as a first-line treatment failed to meaningfully slow the progression of the disease or improve overall survival during a late-stage trial. The Phase 3 LEAP-001...
Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial
Merck & Co. Inc. MRK, -1.66% and Eisai Co. Ltd. ESALF, +3.00% said Friday that a late-stage trial of Merck's blockbuster cancer treatment Keytruda in combination with Eisai's drug Lenvima failed to meet its primary goals for treatment of certain...
Source: https://incomestatements.info
Category: Stock Reports